I now have all the information I need. Let me synthesize the final review.

**Round 1 Bracket:** [6, 7] — The paper is clearly stronger than the rejected Boltzmann generator papers (2.5–3.0) and comparable to topically similar accepted papers in the 5.5–7.0 range.

**Round 2 Narrowing:** I compared against RegFlow (6.67, Poster), PDNS (6.50, Poster), "Enhancing Diffusion-Based Sampling with Molecular CVs" (6.50, Poster), and FALCON (7.00, Oral). CMT has stronger theoretical novelty than RegFlow and PDNS, comparable empirical scope to FALCON, and its weaknesses (hyperparameter guidance) are minor relative to the core contribution. I place it at **6.5**.

---

## Summary

This paper introduces Constrained Mass Transport (CMT), a variational framework for sampling from unnormalized densities (Boltzmann generators) by constructing annealing paths under joint constraints on KL divergence (trust-region) and entropy decay between successive intermediate distributions. The authors derive analytical forms for the optimal intermediate densities under each constraint (Propositions 2.1–2.3), connect them to known annealing paths (Theorem 2.4), and instantiate the framework with normalizing flows. Empirically, CMT outperforms state-of-the-art methods (FAB, TA-BG) across four molecular systems—including the newly introduced ELIL tetrapeptide (d=219)—achieving substantially higher effective sample sizes, better evidence upper bounds, and superior mode coverage.

## Strengths

1. **Strong theoretical foundation with closed-form characterizations.** Propositions 2.1–2.3 provide explicit analytical forms for the optimal intermediate densities under trust-region, entropy, and combined constraints (Equations 5, 8, 10). Theorem 2.4 connects these to geometric, tempered, and geometric-tempered annealing paths with monotonically increasing schedule parameters. This goes beyond heuristic schedule design and gives the framework principled grounding.

2. **Consistent and substantial empirical outperformance.** Table 1 shows CMT achieves the best EUBO, ESS, and Ramachandran TV on all four molecular systems. The gap widens on larger systems: on ELIL tetrapeptide, CMT achieves 26.06% ESS vs. 13.75% (TA-BG) and 7.21% (FAB); on alanine hexapeptide, 29.63% vs. 18.22% (TA-BG). EUBO and Ram TV confirm that the higher ESS reflects genuine distributional fidelity rather than mode collapse.

3. **Ablation study cleanly validates the design.** Figures 2–3 systematically isolate the contribution of each constraint. Removing either constraint leads to visible mode collapse and lower inter-mediate ESS; the combined (geometric-tempered) variant achieves the best target ESS (29.63%) and avoids collapse. This directly validates the core architectural choice.

4. **Introduction of a meaningful new benchmark.** The ELIL tetrapeptide (d=219, complex side-chain interactions) is the largest molecular system studied to date for variational sampling from energy evaluations alone. This provides a harder testbed that highlights CMT's advantage over prior methods.

5. **Negligible computational overhead of the dual optimization.** Section 3 reports that the Lagrangian multiplier optimization accounts for only ~0.01% of total training time on alanine dipeptide, demonstrating practical feasibility.

## Weaknesses

### Fatal
None.

### Major
None.

### Minor
1. **No hyperparameter sensitivity analysis.** The paper fixes ε_tr, ε_ent, and the number of annealing steps T̃ across all experiments for fair benchmarking, but provides no analysis of how these choices affect performance or principled guidance for setting them on new problems. Given that the ablation study shows both constraints matter (Figures 2–3), a practitioner has no information on how to select ε_tr or ε_ent for a problem of different dimensionality or entropy mismatch. This does not undermine the reported results but limits practical reproducibility.

2. **No runtime or scaling breakdown.** The paper reports that dual optimization is ~0.01% of training time for alanine dipeptide, but does not report wall-clock times, scaling trends with dimension, or the number of inner-loop gradient updates per annealing step. The conclusion mentions "the large number of gradient updates needed to approximate each intermediate target" as a limitation without quantification. This makes it hard for readers to evaluate computational cost.

3. **Abstract ESS claim is slightly imprecise.** The abstract says "more than 2.5× higher effective sample size." From Table 1, the largest fold-improvement over the best competing method (TA-BG) is on ELIL (26.06% vs. 13.75% ≈ 1.9×) and alanine hexapeptide (29.63% vs. 18.22% ≈ 1.63×). The 2.5× figure holds against FAB on ELIL (26.06% vs. 7.21% ≈ 3.6×) and alanine hexapeptide (29.63% vs. 14.55% ≈ 2.04×). The claim is defensible but could be read as comparing against all competitors indiscriminately. Minor wording precision issue.

### Trivial
None.

## Nice-to-Haves

- Provide a heuristic for selecting ε_tr and ε_ent (e.g., scale with dimension d, or set ε_ent as a fraction of H(q_0) – H(p)).
- Report empirical variance of the Monte Carlo estimator for Z_{i+1} across training steps to substantiate the claim that trust-region constraints control importance weight variance.
- Report whether the stopping condition λ = η = 0 is ever reached during training, or estimate the number of annealing steps required for convergence.

## Removed Points

- **Criticism about the appendix-stripped claim on importance weight variance** — Removed because the parser strips appendices from all papers; the claim exists in the full submission with supporting evidence in Appendix C.3.
- **"Missing related work"** — Not included per instruction; I do not have external sources to verify omissions.
- **Formatting/presentation nitpicks** — Removed as these are parser artifacts, not author errors.
- **Strawman about the 2.5× claim being a "serious over-statement"** — The harsh critic acknowledged this is a minor imprecision, not a serious issue; I retained a softened version as a Minor weakness.
- **Criticisms about fair comparison that would disfavor the author's method when the asymmetry actually favors the baseline** — No such cases present; all comparisons use the same architecture and comparable or larger budgets for baselines.
- **Generic strength from Strength Finder about "addressing an important problem"** — Removed as unspecific; only concrete, evidenced strengths retained.

## Novel Insights

None beyond the paper's own contributions. The reviewers' observations largely confirm the paper's framing: the constrained optimization framework is sound and the empirical results are convincing, with the main gaps being practical guidance on hyperparameter selection and computational profiling.

## Suggestions

1. Add a sensitivity study (even on one system, e.g., alanine hexapeptide) varying ε_tr and ε_ent to show the method's robustness and help users select these hyperparameters.
2. Report wall-clock time and scaling with dimension, and state the number of gradient updates per annealing step.
3. Slightly rephrase the abstract's "2.5× higher ESS" claim to clarify the specific comparator (e.g., "up to 3.6× higher ESS than FAB on ELIL tetrapeptide and consistently 1.6–1.9× higher than the best baseline on the largest systems").

## Score and Decision

**Score: 6.5** — The paper makes a strong, well-supported contribution: a novel constrained variational framework with closed-form analytical characterizations, comprehensive empirical validation on challenging molecular benchmarks including a new largest-in-literature system, and clean ablations. The weaknesses (hyperparameter guidance, runtime profiling) are real but bounded and do not threaten the core claims. The paper is clearly written and the empirical results consistently favor CMT, often by substantial margins.

**Decision: Accept**

MY FINAL SCORE: <score>6.5</score>
MY FINAL DECISION: <decision>Accept</decision>